# A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

> **NCT07737743** · PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 344 (estimated)

## Conditions studied

- Sjögren's Disease

## Interventions

- **DRUG:** DDY391
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07737743
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-24
- **Primary completion:** 2029-02-19
- **Final completion:** 2029-03-19
- **Target enrollment:** 344 (ESTIMATED)
- **Last updated:** 2026-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07737743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07737743, "A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07737743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*